Geographic Variability and Pathogen-Specific Considerations in the Diagnosis and Management of Chronic Granulomatous Disease

References

• Bridges RA, Berendes H, Good RA. A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndrome. AMA J Dis Child. 1959;97(4):387–408. doi:10.1001/archpedi.1959.0207001038900413636694
   PubMedGoogle Scholar
• Azimi PH, Bodenbender JG, Hintz RL, Kontras SB. Chronic granulomatous disease in three female siblings. JAMA. 1968;206(13):2865–2870. doi:10.1001/jama.1968.031501300230045755008
   PubMed Web of Science ®Google Scholar
• Rider NL, Jameson MB, Creech CB. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S2–S5. doi:10.1093/jpids/piy00829746675
   PubMed Web of Science ®Google Scholar
• Winkelstein JA, Marino MC, Johnston RB, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155–169. doi:10.1097/00005792-200005000-0000310844935
   PubMed Web of Science ®Google Scholar
• Wolach B, Gavrieli R, de Boer M, et al. Chronic granulomatous disease: clinical, functional, molecular, and genetic studies. The Israeli experience with 84 patients. Am J Hematol. 2017;92(1):28–36. doi:10.1002/ajh.2457327701760
   PubMed Web of Science ®Google Scholar
• Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol. 2008;126(2):155–164. doi:10.1016/j.clim.2007.09.00818037347
   PubMed Web of Science ®Google Scholar
• Jones LBKR, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol. 2008;152(2):211–218. doi:10.1111/j.1365-2249.2008.03644.x18410635
   PubMed Web of Science ®Google Scholar
• Tkalcevic J, Novelli M, Phylactides M, Iredale JP, Segal AW, Roes J. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity. 2000;12(2):201–210. doi:10.1016/S1074-7613(00)80173-910714686
   PubMed Web of Science ®Google Scholar
• Reeves EP, Lu H, Jacobs HL, Messina C. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature. 2002;416(6878):291–297. doi:10.1038/416291a11907569
   PubMed Web of Science ®Google Scholar
• Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis. 2010;45(3):246–265. doi:10.1016/j.bcmd.2010.07.01220729109
   PubMed Web of Science ®Google Scholar
• Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis. 2010;44(4):291–299. doi:10.1016/j.bcmd.2010.01.00920167518
   PubMed Web of Science ®Google Scholar
• Arnadottir GA, Norddahl GL, Gudmundsdottir S, et al. A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease. Nat Commun. 2018;9(1):4447. doi:10.1038/s41467-018-06964-x30361506
   PubMed Web of Science ®Google Scholar
• Thomas DC, Charbonnier L-M, Schejtman A, et al. EROS/CYBC1 mutations: decreased NADPH oxidase function and chronic granulomatous disease. J Allergy Clin Immunol. 2019;143(2):782–785.e1. doi:10.1016/j.jaci.2018.09.01930312704
   PubMed Web of Science ®Google Scholar
• Repine JE, Clawson CC, White JG, Holmes B. Spectrum of function of neutrophils from carriers of sex-linked chronic granulomatous disease. J Pediatr. 1975;87(6 Pt 1):901–907. doi:10.1016/S0022-3476(75)80902-41185391
   PubMed Web of Science ®Google Scholar
• Marciano BE, Zerbe CS, Falcone EL, et al. X-linked carriers of chronic granulomatous disease: illness, lyonization, and stability. J Allergy Clin Immunol. 2017. doi:10.1016/j.jaci.2017.04.035
   Web of Science ®Google Scholar
• Lewis EM, Singla M, Sergeant S, Koty PP, McPhail LC. X-linked chronic granulomatous disease secondary to skewed X chromosome inactivation in a female with a novel CYBB mutation and late presentation. Clin Immunol. 2008;129(2):372–380. doi:10.1016/j.clim.2008.07.02218774749
   PubMed Web of Science ®Google Scholar
• Wolach B, Scharf Y, Gavrieli R, de Boer M, Roos D. Unusual late presentation of X-linked chronic granulomatous disease in an adult female with a somatic mosaic for a novel mutation in CYBB. Blood. 2005;105(1):61–66. doi:10.1182/blood-2004-02-067515308575
   PubMed Web of Science ®Google Scholar
• Anderson-Cohen M, Holland SM, Kuhns DB, et al. Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation. Clin Immunol. 2003;109(3):308–317. doi:10.1016/j.clim.2003.08.00214697745
   PubMed Web of Science ®Google Scholar
• Hauck F, Koletzko S, Walz C, et al. Diagnostic and treatment options for severe IBD in female X-CGD carriers with non-random X-inactivation. J Crohns Colitis. 2016;10(1):112–115. doi:10.1093/ecco-jcc/jjv18626464403
   PubMed Web of Science ®Google Scholar
• Rösen-Wolff A, Soldan W, Heyne K, Bickhardt J, Gahr M, Roesler J. Increased susceptibility of a carrier of X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection associated with age-related skewing of lyonization. Ann Hematol. 2001;80(2):113–115. doi:10.1007/s00277000023011261321
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Murayama S, Takanashi S, et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatr. 2008;167(12):1389–1394. doi:10.1007/s00431-008-0680-718335239
   PubMed Web of Science ®Google Scholar
• Köker MY, Camcıoğlu Y, van Leeuwen K, et al. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients. J Allergy Clin Immunol. 2013;132(5):1156–1163.e5. doi:10.1016/j.jaci.2013.05.03923910690
   PubMed Web of Science ®Google Scholar
• Fattahi F, Badalzadeh M, Sedighipour L, et al. Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease. J Clin Immunol. 2011;31(5):792–801. doi:10.1007/s10875-011-9567-x21789723
   PubMed Web of Science ®Google Scholar
• Movahedi M, Aghamohammadi A, Rezaei N, et al. Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry. Int Arch Allergy Immunol. 2004;134(3):253–259. doi:10.1159/00007877415178896
   PubMed Web of Science ®Google Scholar
• Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010;363(27):2600–2610. doi:10.1056/NEJMoa100709721190454
   PubMed Web of Science ®Google Scholar
• Dinauer MC. Inflammatory consequences of inherited disorders affecting neutrophil function. Blood. 2019;133(20):2130–2139. doi:10.1182/blood-2018-11-84456330898864
   PubMed Web of Science ®Google Scholar
• Marciano BE, Spalding C, Fitzgerald A, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60(8):1176–1183. doi:10.1093/cid/ciu115425537876
   PubMed Web of Science ®Google Scholar
• Bennett N, Maglione PJ, Wright BL, Zerbe C. Infectious complications in patients with chronic granulomatous disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S12–S17. doi:10.1093/jpids/piy01329746678
   PubMed Web of Science ®Google Scholar
• Mortaz E, Azempour E, Mansouri D, et al. Common infections and target organs associated with chronic granulomatous disease in Iran. Int Arch Allergy Immunol. 2019;179(1):62–73. doi:10.1159/00049618130904913
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. 2007;45(6):673–681. doi:10.1086/52098517712749
   PubMed Web of Science ®Google Scholar
• Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am. 2013;27(1):89–99–viii. doi:10.1016/j.hoc.2012.11.002
   Web of Science ®Google Scholar
• Álvarez-Cardona A, Rodríguez-Lozano AL, Blancas-Galicia L, Rivas-Larrauri FE, Yamazaki-Nakashimada MA. Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease. J Clin Immunol. 2012;32(2):207–211. doi:10.1007/s10875-011-9616-522119934
   PubMed Web of Science ®Google Scholar
• Akagi K, Kawai T, Watanabe N, et al. A case of macrophage activation syndrome developing in a patient with chronic granulomatous disease-associated colitis. J Pediatr Hematol Oncol. 2014;36(3):e169–e172. doi:10.1097/MPH.0b013e31828e5dae23652865
   PubMed Web of Science ®Google Scholar
• Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114(2):462–468. doi:10.1542/peds.114.2.46215286231
   PubMed Web of Science ®Google Scholar
• Walther MM, Malech H, Berman A, et al. The urological manifestations of chronic granulomatous disease. J Urol. 1992;147(5):1314–1318. doi:10.1016/S0022-5347(17)37552-31569675
   PubMed Web of Science ®Google Scholar
• Henrickson SE, Jongco AM, Thomsen KF, Garabedian EK, Thomsen IP. Noninfectious manifestations and complications of chronic granulomatous disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S18–S24. doi:10.1093/jpids/piy01429746679
   PubMed Web of Science ®Google Scholar
• Barese CN, Podestá M, Litvak E, Villa M, Rivas EM. Recurrent eosinophilic cystitis in a child with chronic granulomatous disease. J Pediatr Hematol Oncol. 2004;26(3):209–212. doi:10.1097/00043426-200403000-0001415125617
   PubMed Web of Science ®Google Scholar
• Battersby AC, Braggins H, Pearce MS, et al. Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom. J Allergy Clin Immunol. 2017;140(2):628–630.e6. doi:10.1016/j.jaci.2017.02.02928343844
   PubMed Web of Science ®Google Scholar
• Bortoletto P, Lyman K, Camacho A, Fricchione M, Khanolkar A, Katz BZ. Chronic granulomatous disease: a large, single-center US experience. Pediatr Infect Dis J. 2015;34(10):1110–1114. doi:10.1097/INF.000000000000084026181896
   PubMed Web of Science ®Google Scholar
• Reichenbach J, Lopatin U, Mahlaoui N, et al. Actinomyces in chronic granulomatous disease: an emerging and unanticipated pathogen. Clin Infect Dis. 2009;49(11):1703–1710. doi:10.1086/64794519874205
   PubMed Web of Science ®Google Scholar
• Sugui JA, Peterson SW, Clark LP, et al. Aspergillus tanneri sp. nov., a new pathogen that causes invasive disease refractory to antifungal therapy. J Clin Microbiol. 2012;50(10):3309–3317. doi:10.1128/JCM.01509-1222855513
   PubMed Web of Science ®Google Scholar
• Haidar G, Zerbe CS, Cheng M, Zelazny AM, Holland SM, Sheridan KR. Phellinus species: an emerging cause of refractory fungal infections in patients with X-linked chronic granulomatous disease. Mycoses. 2017;60(3):155–160. doi:10.1111/myc.1257327781311
   PubMed Web of Science ®Google Scholar
• Greenberg DE, Ding L, Zelazny AM, et al. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog. 2006;2(4):e28. doi:10.1371/journal.ppat.002002816617373
   PubMed Web of Science ®Google Scholar
• Meher-Homji Z, Mangalore RP, Johnson PD, Chua KY. Chromobacterium violaceum infection in chronic granulomatous disease: a case report and review of the literature. JMM Case Rep. 2017;4(1):e005084. doi:10.1099/jmmcr.0.00508428348801
   PubMedGoogle Scholar
• Relich RF, Humphries RM, Mattison HR, et al. Francisella philomiragia bacteremia in a patient with acute respiratory insufficiency and acute-on-chronic kidney disease. J Clin Microbiol. 2015;53(12):3947–3950. doi:10.1128/JCM.01762-1526400786
   PubMed Web of Science ®Google Scholar
• Macher AM, Casale TB, Fauci AS. Chronic granulomatous disease of childhood and Chromobacterium violaceum infections in the southeastern United States. Ann Intern Med. 1982;97(1):51–55. doi:10.7326/0003-4819-97-1-517092006
   PubMed Web of Science ®Google Scholar
• van den Berg JM, van Koppen E, Åhlin A, et al. Chronic granulomatous disease: the European experience. PLoS One. 2009;4(4):e5234. doi:10.1371/journal.pone.000523419381301
   PubMed Web of Science ®Google Scholar
• Rawat A, Vignesh P, Sharma A, et al. Infection profile in chronic granulomatous disease: a 23-year experience from a tertiary care center in North India. J Clin Immunol. 2017;37(3):319–328. doi:10.1007/s10875-017-0382-x28332028
   PubMed Web of Science ®Google Scholar
• Wolach B, Gavrieli R, de Boer M, et al. Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients. Clin Immunol. 2008;129(1):103–114. doi:10.1016/j.clim.2008.06.01218708296
   PubMed Web of Science ®Google Scholar
• de Oliveira-junior EB, Zurro NB, Prando C, et al. Clinical and genotypic spectrum of chronic granulomatous disease in 71 Latin American patients: first report from the LASID registry. Pediatr Blood Cancer. 2015;62(12):2101–2107. doi:10.1002/pbc.2567426185101
   PubMed Web of Science ®Google Scholar
• Blancas-Galicia L, Santos-Chávez E, Deswarte C, et al. Genetic, immunological, and clinical features of the first mexican cohort of patients with chronic granulomatous disease. J Clin Immunol. 2020;40(3):475–493. doi:10.1007/s10875-020-00750-532040803
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2018. 2018.
   Google Scholar
• Stewart RJ, Tsang CA, Pratt RH, Price SF, Langer AJ. Tuberculosis - United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67(11):317–323. doi:10.15585/mmwr.mm6711a229565838
   PubMed Web of Science ®Google Scholar
• Calmette A. Preventive vaccination against tuberculosis with BCG. Proc R Soc Med. 1931;24(11):1481–1490.19988326
   PubMedGoogle Scholar
• BCG vaccines. WHO position paper – february 2018. Wkly Epidemiol Rec. 2018;93(8):73–96.29474026
   PubMedGoogle Scholar
• Norouzi S, Aghamohammadi A, Mamishi S, Rosenzweig SD, Rezaei N. Bacillus calmette-guérin (BCG) complications associated with primary immunodeficiency diseases. J Infect. 2012;64(6):543–554. doi:10.1016/j.jinf.2012.03.01222430715
   PubMed Web of Science ®Google Scholar
• Zhou Q, Hui X, Ying W, et al. A cohort of 169 chronic granulomatous disease patients exposed to BCG vaccination: a retrospective study from a single center in Shanghai, China (2004–2017). J Clin Immunol. 2018;38(3):260–272. doi:10.1007/s10875-018-0486-y29560547
   PubMed Web of Science ®Google Scholar
• Baba LA, Ailal F, El Hafidi N, et al. Chronic granulomatous disease in Morocco: genetic, immunological, and clinical features of 12 patients from 10 kindreds. J Clin Immunol. 2014;34(4):452–458. doi:10.1007/s10875-014-9997-324596025
   PubMed Web of Science ®Google Scholar
• Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012. doi:10.1371/journal.pmed.100101221445325
   PubMed Web of Science ®Google Scholar
• Lee PPW, Chan K-W, Jiang L, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J. 2008;27(3):224–230. doi:10.1097/INF.0b013e31815b494c18277931
   PubMed Web of Science ®Google Scholar
• Conti F, Lugo-Reyes SO, Blancas-Galicia L, et al. Mycobacterial disease in patients with chronic granulomatous disease: a retrospective analysis of 71 cases. J Allergy Clin Immunol. 2016;138(1):241–248.e243. doi:10.1016/j.jaci.2015.11.04126936803
   PubMed Web of Science ®Google Scholar
• Fernando SJA, Faiz NM, Handunnetti SM, et al. Preliminary study on chronic granulomatous disease in Sri Lanka. Allergy Asthma Clin Immunol. 2018;14(1):37. doi:10.1186/s13223-018-0264-730237823
   PubMed Web of Science ®Google Scholar
• Khanna G, Kao SC, Kirby P, Sato Y. Imaging of chronic granulomatous disease in children. Radiographics. 2005;25(5):1183–1195. doi:10.1148/rg.25505501116160105
   PubMed Web of Science ®Google Scholar
• Henriet S, Verweij PE, Holland SM, Warris A. Invasive fungal infections in patients with chronic granulomatous disease. Adv Exp Med Biol. 2013;764:27–55. doi:10.1007/978-1-4614-4726-9_323654055
   PubMed Web of Science ®Google Scholar
• Greenberg DE, Shoffner AR, Zelazny AM, et al. Recurrent granulibacter bethesdensis infections and chronic granulomatous disease. Emerg Infect Dis. 2010;16(9):1341–1348. doi:10.3201/eid1609.09180020735916
   PubMed Web of Science ®Google Scholar
• Silliman CC, Lawellin DW, Lohr JA, Rodgers BM, Donowitz LG. Paecilomyces lilacinus infection in a child with chronic granulomatous disease. J Infect. 1992;24(2):191–195. doi:10.1016/0163-4453(92)92980-W1533235
   PubMed Web of Science ®Google Scholar
• White PL, Wingard JR, Bretagne S, et al. Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing. Clin Infect Dis. 2015;61(8):1293–1303. doi:10.1093/cid/civ50726113653
   PubMed Web of Science ®Google Scholar
• Wang Y, Marciano BE, Shen D, et al. Molecular identification of bacterial DNA in the chorioretinal scars of chronic granulomatous disease. J Clin Immunol. 2013;33(5):917–924. doi:10.1007/s10875-013-9899-923636897
   PubMed Web of Science ®Google Scholar
• Hong DK, Blauwkamp TA, Kertesz M, Bercovici S, Truong C, Banaei N. Liquid biopsy for infectious diseases: sequencing of cell-free plasma to detect pathogen DNA in patients with invasive fungal disease. Diagn Microbiol Infect Dis. 2018;92(3):210–213. doi:10.1016/j.diagmicrobio.2018.06.00930017314
   PubMed Web of Science ®Google Scholar
• Schlaberg R, Chiu CY, Miller S, et al. Validation of metagenomic next-generation sequencing tests for universal pathogen detection. Arch Pathol Lab Med. 2017;141(6):776–786. doi:10.5858/arpa.2016-0539-RA28169558
   PubMed Web of Science ®Google Scholar
• Yu JE, Azar AE, Chong HJ, Jongco AM, Prince BT. Considerations in the diagnosis of chronic granulomatous disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S6–S11. doi:10.1093/jpids/piy00729746674
   PubMed Web of Science ®Google Scholar
• Banerjee R, Anguita J, Roos D, Fikrig E. Cutting edge: infection by the agent of human granulocytic ehrlichiosis prevents the respiratory burst by down-regulating gp91phox. J Immunol. 2000;164(8):3946–3949. doi:10.4049/jimmunol.164.8.394610754283
   PubMed Web of Science ®Google Scholar
• Mauch L, Lun A, O’Gorman MRG, et al. Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem. 2007;53(5):890–896. doi:10.1373/clinchem.2006.08344417384005
   PubMed Web of Science ®Google Scholar
• Ochs HD, Igo RP. The NBT slide test: a simple screening method for detecting chronic granulomatous disease and female carriers. J Pediatr. 1973;83(1):77–82. doi:10.1016/S0022-3476(73)80316-64768939
   PubMed Web of Science ®Google Scholar
• Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol. 2014;175(2):139–149. doi:10.1111/cei.1220224016250
   PubMed Web of Science ®Google Scholar
• Görlach A, Lee PL, Roesler J, et al. A p47-phox pseudogene carries the most common mutation causing p47-phox- deficient chronic granulomatous disease. J Clin Invest. 1997;100(8):1907–1918. doi:10.1172/JCI1197219329953
   PubMed Web of Science ®Google Scholar
• Thomsen IP, Smith MA, Holland SM, Creech CB. A comprehensive approach to the management of children and adults with chronic granulomatous disease. J Allergy Clin Immunol Pract. 2016;4(6):1082–1088. doi:10.1016/j.jaip.2016.03.02127178966
   PubMed Web of Science ®Google Scholar
• Kuruvilla M, La MorenaDe MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract. 2013;1(6):573–582. doi:10.1016/j.jaip.2013.09.01324565703
   PubMed Web of Science ®Google Scholar
• Slack MA, Thomsen IP. Prevention of infectious complications in patients with chronic granulomatous disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S25–S30. doi:10.1093/jpids/piy01629746681
   PubMed Web of Science ®Google Scholar
• Ezekowitz RA, Orkin SH, Newburger PE. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest. 1987;80(4):1009–1016. doi:10.1172/JCI1131532821069
   PubMed Web of Science ®Google Scholar
• Condino-Neto A, Newburger PE. Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splice site consensus region mutation. Blood. 2000;95(11):3548–3554. doi:10.1182/blood.V95.11.354810828042
   PubMed Web of Science ®Google Scholar
• Sechler JG. Recombinant Human Interferon-y Reconstitutes Defective Phagocyte Function in Patients with Chronic Granulomatous Disease Ofchildhood. 2005 1 1–5.
   Google Scholar
• International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The international chronic granulomatous disease cooperative study group. N Engl J Med. 1991;324(8):509–516. doi:10.1056/NEJM1991022132408011846940
   PubMed Web of Science ®Google Scholar
• Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis. 2004;39(5):692–699. doi:10.1086/42299315356785
   PubMed Web of Science ®Google Scholar
• Leiding JW, Freeman AF, Marciano BE, et al. Corticosteroid therapy for liver abscess in chronic granulomatous disease. Clin Infect Dis. 2012;54(5):694–700. doi:10.1093/cid/cir89622157170
   PubMed Web of Science ®Google Scholar
• Straughan DM, McLoughlin KC, Mullinax JE, et al. The changing paradigm of management of liver abscesses in chronic granulomatous disease. Clin Infect Dis. 2018;66(9):1427–1434. doi:10.1093/cid/cix101229145578
   PubMed Web of Science ®Google Scholar
• Chin TW, Stiehm ER, Falloon J, Gallin JI. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J Pediatr. 1987;111(3):349–352. doi:10.1016/s0022-3476(87)80452-33625401
   PubMed Web of Science ®Google Scholar
• Hahn KJ, Ho N, Yockey L, et al. Treatment with anakinra, a recombinant IL-1 receptor antagonist, unlikely to induce lasting remission in patients with CGD colitis. Am J Gastroenterol. 2015;110(6):938–939. doi:10.1038/ajg.2015.13526052777
   PubMed Web of Science ®Google Scholar
• Butte MJ, Park KT, Lewis DB. Treatment of CGD-associated colitis with the IL-23 blocker ustekinumab. J Clin Immunol. 2016;36(7):619–620. doi:10.1007/s10875-016-0318-x27465505
   PubMed Web of Science ®Google Scholar
• Campbell N, Chapdelaine H. Treatment of chronic granulomatous disease-associated fistulising colitis with vedolizumab. J Allergy Clin Immunol Pract. 2017;5(6):1748–1749. doi:10.1016/j.jaip.2017.07.03528919373
   PubMed Web of Science ®Google Scholar
• Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010;51(12):1429–1434. doi:10.1086/65730821058909
   PubMed Web of Science ®Google Scholar
• Soncini E, Slatter MA, Jones LBKR, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol. 2009;145(1):73–83. doi:10.1111/j.1365-2141.2009.07614.x19222467
   PubMed Web of Science ®Google Scholar
• Schuetz C, Hoenig M, Gatz S, et al. Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease. Immunol Res. 2009;44(1–3):35–41. doi:10.1007/s12026-008-8068-318846320
   PubMed Web of Science ®Google Scholar
• Goździk J, Pituch-Noworolska A, Skoczeń S, et al. Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease–single centre experience. J Clin Immunol. 2011;31(3):332–337. doi:10.1007/s10875-011-9513-y21384251
   PubMed Web of Science ®Google Scholar
• Martinez CA, Shah S, Shearer WT, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012;129(1):176–183. doi:10.1016/j.jaci.2011.10.00522078471
   PubMed Web of Science ®Google Scholar
• Tewari P, Martin PL, Mendizabal A, et al. Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. Biol Blood Marrow Transplant. 2012;18(9):1368–1377. doi:10.1016/j.bbmt.2012.02.00222326631
   PubMed Web of Science ®Google Scholar
• Morillo-Gutierrez B, Beier R, Rao K, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128(3):440–448. doi:10.1182/blood-2016-03-70401527216217
   PubMed Web of Science ®Google Scholar
• Mehta B, Mahadeo K, Kapoor N, Abdel-Azim H. Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease. Pediatr Transplant. 2015;19(4):408–412. doi:10.1111/petr.1247125845644
   PubMed Web of Science ®Google Scholar
• Lum SH, Flood T, Hambleton S, et al. Two decades of excellent transplant survival for chronic granulomatous disease: a supraregional immunology transplant center report. Blood. 2019;133(23):2546–2549. doi:10.1182/blood.201900002130952673
   PubMed Web of Science ®Google Scholar
• Cole T, Pearce MS, Cant AJ, Cale CM, Goldblatt D, Gennery AR. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;132(5):1150–1155. doi:10.1016/j.jaci.2013.05.03123870668
   PubMed Web of Science ®Google Scholar
• Cole T, McKendrick F, Titman P, et al. Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol. 2013;33(1):8–13. doi:10.1007/s10875-012-9758-023011479
   PubMed Web of Science ®Google Scholar
• Seger RA, Güngör T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood. 2002;100(13):4344–4350. doi:10.1182/blood-2002-02-058312393596
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. 2001;344(12):881–888. doi:10.1056/NEJM20010322344120311259721
   PubMed Web of Science ®Google Scholar
• Güngör T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436–448. doi:10.1016/S0140-6736(13)62069-324161820
   PubMed Web of Science ®Google Scholar
• Parta M, Kelly C, Kwatemaa N, et al. Allogeneic reduced-intensity hematopoietic stem cell transplantation for chronic granulomatous disease: a single-center prospective trial. J Clin Immunol. 2017;37(6):548–558. doi:10.1007/s10875-017-0422-628752258
   PubMed Web of Science ®Google Scholar
• Fox TA, Chakraverty R, Burns S, et al. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood. 2018;131(8):917–931. doi:10.1182/blood-2017-09-80748729279357
   PubMed Web of Science ®Google Scholar
• Arnold DE, Seif AE, Jyonouchi S, Sullivan KE, Bunin NJ, Heimall JR. Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease. J Allergy Clin Immunol Pract. 2019;7(3):1052–1054.e1052. doi:10.1016/j.jaip.2018.10.03430391552
   PubMed Web of Science ®Google Scholar
• Marsh RA, Leiding JW, Logan BR, et al. Chronic granulomatous disease-associated ibd resolves and does not adversely impact survival following allogeneic HCT. J Clin Immunol. 2019;39(7):653–667. doi:10.1007/s10875-019-00659-831376032
   PubMed Web of Science ®Google Scholar
• Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401–409. doi:10.1038/nm139316582916
   PubMed Web of Science ®Google Scholar
• Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood. 2009;114(13):2619–2622. doi:10.1182/blood-2009-05-22160619541821
   PubMed Web of Science ®Google Scholar
• Kang HJ, Bartholomae CC, Paruzynski A, et al. Retroviral gene therapy for X-linked chronic granulomatous disease: results from Phase I/II trial. Mol Ther. 2011;19(11):2092–2101. doi:10.1038/mt.2011.16621878903
   PubMed Web of Science ®Google Scholar
• Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2):198–204. doi:10.1038/nm.208820098431
   PubMed Web of Science ®Google Scholar
• Keller MD, Notarangelo LD, Malech HL. Future of care for patients with chronic granulomatous disease: gene therapy and targeted molecular medicine. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S40–S44. doi:10.1093/jpids/piy01129746676
   PubMed Web of Science ®Google Scholar